number of downloads : ?
File
language
eng
Attribute
Review
Author
ISHIHARA, Shunji Department of Internal Medicine II, Shimane University Faculty of Medicine
MISHIMA, Yoshiyuki Department of Internal Medicine II, Shimane University Faculty of Medicine
KAWASHIMA, Kosaku Department of Internal Medicine II, Shimane University Faculty of Medicine
Description
Crohn’s disease (CD) is an immune-mediated inflammatory intestinal disease of unknown etiology. In addition to conventional drugs such as 5-aminosalicylates (5-ASA), corticosteroids, and immune-modulating drugs, biologics targeting inflammation- and immunerelated molecules have been developed for treating CD. Initially, anti-tumor necrosis factor (TNF)-α antibodies were used for induction and maintenance therapies, and the clinical course of affected patients was dramatically changed because of their efficacy and safety. More recently, novel humanized biologics targeting the p40-subunit of interleukin (IL)-12/23 and α4β7-integrin have been developed, and shown to contribute to longterm therapy for CD. Although the efficacy of biologics for CD is widely recognized, how to determine which biologic is appropriate for individual patients remains largely unknown and additional studies are necessary to clarify this issue.
Subject
cystatin C
protease inhibitor
cerebrospinal fluid
inflammatory neurological diseases
neurodegenerative diseases
Journal Title
Shimane Journal of Medical Science
Volume
37
Issue
2
Start Page
45
End Page
50
ISSN
03865959
ISSN(Online)
24332410
Published Date
2020-06
NCID
AA00841586
Publisher
Faculty of Medicine, Shimane University
Publisher Aalternative
島根大学医学部
NII Type
Departmental Bulletin Paper
Format
PDF
Rights
Faculty of Medicine, Shimane University
Text Version
出版社版
OAI-PMH Set
Faculty of Medicine
このエントリーをはてなブックマークに追加